Skip to content

BelCoPhar

Active
Private limited companyfounded 20224 years activeHeiken (Ab) 5, 2920 Kalmthout, BelgiumKBO/BCE: BE 0789.518.434
Summary

BelCoPhar has been active since 2022 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €176,428 and a net result of €28,535. Equity is growing by ~29% per year across the filed fiscal years. Its solvency ranks better than 80% of 72 sector peers (NACE 21, fiscal year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).

Overview

Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparations
NACE 21201
2 sites
Size
€224,468total assets 2025
Equity
€176,428
Profit
€28,535
Turnover not published (abridged schema)
Financial health
90 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
0.3%
Structure
Largest shareholder
WEBINVEST · 50%
Accounts filed 61 days late
Why 90- Latest accounts 61 days late; 2 of the last 3 late+ Liquidity: current ratio 3.66, cash €115,872+ Equity €176,428 (78.6% of total assets)+ Sector Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21)Show the evidence

Checked score

Score 2025
90 / 100
Excellent
Probability in this band: under 0.55%
Financially better than 82% of its sector peers (NACE 21, micro)
Financial strength · tick = 2024
Strong
Solvency 100=
equity 78.6% of total assets
Liquidity 94+8
short-term debt 20.3% · cash 51.6%
Profitability 85-15
return on assets 12.7%
Bankruptcy probability, 12 months
0.3% Very low
0%0.5%1.5%4%10%≥ 25%

About 3 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.3% (154 companies)
Last 24 months 11-2024: 0.3% 12-2024: 0.3%● unchanged vs 11-2024 01-2025: 0.2%▼ -0.1 percentage points vs 12-2024 02-2025: 0.2%● unchanged vs 01-2025 03-2025: 0.2%● unchanged vs 02-2025 04-2025: 0.2%● unchanged vs 03-2025lowest value 05-2025: 0.3%▲ +0.1 percentage points vs 04-2025 06-2025: 0.3%● unchanged vs 05-2025 07-2025: 0.3%● unchanged vs 06-2025 08-2025: 0.4%▲ +0.1 percentage points vs 07-2025 09-2025: 0.4%● unchanged vs 08-2025 10-2025: 0.4%● unchanged vs 09-2025 11-2025: 0.4%● unchanged vs 10-2025 12-2025: 0.4%● unchanged vs 11-2025 01-2026: 0.4%● unchanged vs 12-2025 02-2026: 0.4%● unchanged vs 01-2026 03-2026: 0.4%● unchanged vs 02-2026 04-2026: 0.3%▼ -0.1 percentage points vs 03-2026 05-2026: 0.3%● unchanged vs 04-2026 06-2026: 0.3%● unchanged vs 05-2026 07-2026: 0.3%● unchanged vs 06-2026 08-2026: 0.6%▲ +0.3 percentage points vs 07-2026 09-2026: 0.7%▲ +0.1 percentage points vs 08-2026highest value 10-2026: 0.3%▼ -0.4 percentage points vs 09-2026
Credit up to €15,000 at 30 days acceptable
Liquidity ample (current ratio 3.66 against 2.77 in 2024; short-term debt: 20.3% and cash: 51.6% of total assets), and 21.4% of the assets are financed with debt.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 21, micro): better than 90% on solvency, 86% on liquidity, 77% on profitability and 73% on growth.

The bankruptcy probability was computed on 07-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum : and see how the verdict changes with amount, term and advance.

Signals

Five signals.
−lowers risk+raises risk○neutral
lowers risk · Liquidity: current ratio 3.66, cash €115,872
NBB · annual accounts
raises risk · Latest accounts 61 days late; 2 of the last 3 late
NBB · filings
lowers risk · Equity €176,428 (78.6% of total assets)
NBB · annual accounts
lowers risk · Sector Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21)
KBO
neutral · Filed after the deadline
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 30-09-2026, 61 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 3 filings
Deviation from the deadline
2025
61 days late
2024
29 days late
2023
82 days late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 3 accounts on average 57 days after the deadline; the sector median for financial year 2024 is 9 days before the deadline, and 32% of the sector filed late.

Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 30 September (3 of the last 3 filed years within 32 days of that day).
Companies Code · seven months
Position in the running window
08-10-2026 today31-12-2026 close31-07-2027 deadline
neutral · No strike-offs in the KBO publications
Checked from 2021 on.
KBO publications · our coverage
  1. Annual accounts filedfiscal year 2025 · micro…
  2. Weakest financial yearnet €28,535 ▼50.2%
  3. Equity above €150,000Eq €176,428 ▲19.3%

Key points

  • Caution: Latest accounts filed lateafter the legal deadline 61 days View
  • Total assets 20253 fiscal years filed €224,468 View
  • Active since 2022founded 09-08-2022 4 years View

By topic

Financials

Fiscal year
2025
Total assets
€224,468
Profit
€28,535
Solvency
78.6%
Total assets▲ 14.3%
Net result
20232025
Go to Financials

Timeline

Events
6
Since
2024
Next accounts
by 31-07-2027
  1. 29-08-2025Annual accounts filed
  2. 31-12-2024Equity above €100,000
  3. 21-10-2024Annual accounts filed
Go to Timeline

Company details

Sites
2
Legal form
Private limited company
Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21201
Founded
09-08-2022
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Go further with this company

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.